CIBC Asset Management’s Blueprint Medicines BPMC Stock Holding History

CIBC Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,928	Closed	-$247K	–	1247
2025 Q2	$247K	Buy	+1,928	New	+$200K	﹤0.01%	984
2022 Q1	–	Sell	-2,536	Closed	-$272K	–	1530
2021 Q4	$272K	Buy	2,536 +168	+7%	+$17.6K	﹤0.01%	1140
2021 Q3	$243K	Buy	+2,368	New	+$221K	﹤0.01%	1180
2021 Q2	–	Sell	-2,075	Closed	-$202K	–	1367
2021 Q1	$202K	Buy	2,075 +151	+8%	+$15.1K	﹤0.01%	1248
2020 Q4	$216K	Buy	+1,924	New	+$203K	﹤0.01%	1096

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

CIBC Asset Management's BPMC Position: Q3 2025 in Review

CIBC Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,928 shares — an estimated $247K sold.

CIBC Asset Management first reported a position in BPMC in Q4 2020 and held it in 5 quarters. The position peaked at $272K in Q4 2021. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

CIBC Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
CIBC Asset Management sold 1,928 Blueprint Medicines shares in Q3 2025, an estimated $247K.
CIBC Asset Management first reported a position in Blueprint Medicines in Q4 2020 and held it in 5 quarters.
CIBC Asset Management's Blueprint Medicines position peaked at $272K in Q4 2021.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on CIBC Asset Management's 13F filing for Q3 2025, filed 31 Oct 2025.